Choosing between Axsome Therapeutics (NASDAQ:AXSM) and Vertex Pharmaceuticals (NASDAQ:VRTX) means weighing aggressive revenue growth against established, highly profitable dominance in the global biotechnology market. Which is the better buy today?

Axsome focuses on central nervous system disorders with a rapidly expanding commercial portfolio, while Vertex is a cash flow powerhouse led by its cystic fibrosis treatments. Both companies represent different risk and reward profiles in the healthcare market, making them favorites for various types of investors.

The case for Axsome Therapeutics

Axsome Therapeutics focuses on developing and commercializing therapies for central nervous system conditions, including depression, migraine, and narcolepsy. As a growing player among biotech stocks, the company generates revenue from its approved products, Auvelity and Sunosi. It has recently resolved patent litigation for Sunosi through settlement agreements that establish a framework for generic entry starting in 2040, providing long-term clarity for that specific product line.

In FY 2025, revenue reached nearly $638.5 million, representing a significant growth of roughly 65.5% compared to the previous year. Despite this rapid expansion in sales, the company reported a net loss of approximately $183.2 million for the period. This net margin, which measures the percentage of revenue remaining as profit after all expenses, was a negative 28.7%, which was an improvement from deeper losses in prior years.

As of its December 2025 balance sheet, the debt-to-equity ratio is roughly 2.7x, meaning total debt is nearly three times the value of shareholder equity. The current ratio, which measures a company's ability to cover its short-term obligations with short-term assets, is approximately 1.4x. During FY 2025, free cash flow was negative $93.9 million, which is the cash remaining after the business paid for its operations and capital investments.

The case for Vertex Pharmaceuticals

Vertex Pharmaceuticals is a biotechnology leader known for its portfolio of medicines treating cystic fibrosis, such as Trikafta and Kalydeco. The company also markets therapies for sickle cell disease and has recently introduced Journavx for acute pain management. By maintaining extensive networks of authorized treatment centers and broad payer coverage, the business ensures its specialized therapies reach patients across global markets.

In FY 2025, revenue reached approximately $12.1 billion, which reflects a year over year growth of nearly 9.6%. The company is highly profitable, reporting net income of close to $4.0 billion for the fiscal year. This resulted in a net margin of approximately 32.7%, showing that Vertex retains nearly a third of its revenue as profit after accounting for all of its costs.

As of its December 2025 balance sheet, the debt-to-equity ratio is close to 0.2x, indicating that total debt is quite low relative to shareholder equity. Its current ratio is approximately 2.9x, suggesting a strong ability to meet short-term financial commitments with its existing assets. The company generated roughly $3.2 billion in free cash flow during FY 2025, which represents the cash left over after paying for operations and capital equipment.

Risk profile comparison

Axsome faces several operational and financial risks, including a history of net losses and a recurring need for additional funding to sustain its clinical trials. The company also deals with competition from generic versions of its products, such as recent regulatory filings for generic Auvelity and Symbravo. Regulatory hurdles remain a challenge, illustrated by a previous Refuse to File letter for its candidate AXS-14, alongside a heavy dependence on third-party manufacturers for supply.

Vertex contends with significant revenue concentration since most of its sales come from cystic fibrosis treatments, making it vulnerable to any manufacturing or safety disruptions in that area. Product development is complex and carries risks of failure, such as the setback for its VX-264 program. Furthermore, the company faces pricing pressures from government regulators and must successfully integrate acquisitions like Crinetics Pharmaceuticals and Alpine Immune Sciences while competing with CRISPR Therapeutics (NASDAQ:CRSP).

Valuation comparison

Vertex appears more conservatively valued based on its Forward P/E relative to future earnings estimates, while Axsome commands a higher P/S ratio measuring price against sales.

Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

I'd go with Vertex Pharmaceuticals. It has built one of the most profitable and diversified drug portfolios in biotech, and the pipeline keeps expanding into new disease areas that could sustain that growth for years. Its cystic fibrosis franchise now treats the vast majority of patients living with the disease, and a new pain drug is gaining commercial traction alongside it. A recently completed acquisition adds a kidney disease drug awaiting an imminent FDA approval decision. The balance sheet is flush with cash, and management just raised its full-year outlook.

Axsome has quickly built a very strong commercial drug portfolio, with a new FDA approval for a condition affecting many Alzheimer's patients adding a promising new indication. For investors who want earlier-stage biotech exposure with commercial products already on the market, it is a good candidate.

The challenge for Axsome right now is that building a commercial drug business is expensive, and the costs are rising faster than the revenue. Missing estimates in the most recent quarter is a reminder that the path to profitability leaves little room for stumbles. Vertex faces no such uncertainty. It has already done the hard work of building a profitable, diversified business, and it keeps adding to it. That's why it's my pick.

Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Axsome Therapeutics and Vertex Pharmaceuticals. The Motley Fool recommends CRISPR Therapeutics. The Motley Fool has a disclosure policy.

Bristol Myers Squibb: Slow and Steady Revenue Growth

Bristol Myers Squibb (NYSE:BMY) operates as a global biopharmaceutical entity that researches, develops, and commercializes a worldwide medicinal portfolio spanning therapeutic areas like hematology, oncology, and cardiovascular health, offering pharmaceutical products such as Revlimid and Eliquis.

It received accelerated regulatory approval from the U.S. Food and Drug Administration for its Zenbexus combination therapy for adult patients with multiple myeloma in August 2026, and it selected Houston for a new $2.3 billion multi-modal manufacturing campus designed to increase its production capacity for next-generation medicines.

Johnson & Johnson: Maintaining a Larger Revenue Base

Johnson & Johnson (NYSE:JNJ) functions as a broad healthcare holding company that engages in the research, development, manufacture, and global sale of products primarily through its dedicated innovative medicine and medical technology segments.

It finalized a $1 billion cash acquisition of Firefly Bio in July 2026 to integrate a targeted antibody-drug conjugate platform, while it also secured regulatory approval for its IMAAVY treatment for patients dealing with warm autoimmune hemolytic anemia.

Why Revenue Matters for Investors

Revenue here refers to the data provider's standardized income-statement revenue line item, which gives investors a direct baseline measurement of the total volume of money a business brings in from its core commercial operations before deducting any associated operating expenses, interest, or taxes.

Comparing Quarterly Revenue for Bristol Myers Squibb and Johnson & Johnson

Data source: Financial Modeling Prep. Data as of Sept. 25, 2026.

Foolish Take

Both Bristol Myers Squibb and Johnson & Johnson are consistently, if slowly, growing their revenue, though Johnson & Johnson is obviously starting from a much larger base. In fact, despite Johnson & Johnson's revenue being about double that of Bristol Myers Squibb, over the period shown above, it grew its revenue at a slightly higher rate. That's impressive.

One thing to watch from here will be Johnson & Johnson's medical technology division, an area Bristol Myers Squibb, a biopharmaceuticals company, doesn't have. J&J's medtech division grew operational sales 3.6% in the second quarter, and in 2025, it generated $33.79 billion in revenue. It's growing the segment via both acquisitions and in-house research and development, which can be costly. However, once those products are approved and in use, they can generate exceptional revenue and high profit margins.

In July, J&J received FDA market authorization in the U.S. for its OTTAVA Robotic Surgical System, "the world's first table-integrated soft tissue robotic system." At the time of the announcement, a U.S. clinical trial for OTTAVA in inguinal hernia procedures was ongoing. Customer uptake and success with this system could provide a strong moat and a new recurring revenue stream for the legacy healthcare company.

Sarah Sidlow has positions in Johnson & Johnson. The Motley Fool has positions in and recommends Bristol Myers Squibb. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

As healthcare costs and procedure volumes continue to shift globally, investors must decide between two titans of the industry. Choosing between Abbott Laboratories (NYSE:ABT) and Intuitive Surgical (NASDAQ:ISRG) requires weighing diversified stability against high-growth specialized technology.

Abbott provides a broad array of medical products used in daily care, while Intuitive focuses on the specialized niche of robotic-assisted surgery. These companies are often compared because they represent different ways to invest in the future of medical technology and hospital spending.

The case for Abbott Laboratories

Abbott Laboratories operates a diversified business model that spans diabetes care, cardiovascular devices, diagnostics, and nutrition. It sells products to a wide range of customers, including hospitals, wholesalers, and government agencies, which helps it weather fluctuations in any single market. In early 2026, the company entered a definitive agreement to acquire Exact Sciences to strengthen its presence in the cancer diagnostics market.

In FY 2025, revenue reached nearly $44.3 billion, representing a growth of roughly 5.7% compared to the previous year. The company reported net income of approximately $6.5 billion for the period, resulting in a net margin of close to 14.7%. This performance reflects steady demand across its various healthcare segments, particularly in its medical device and diagnostic divisions.

Abbott maintains a stable financial position with a debt-to-equity ratio of nearly 0.3x as of its December 2025 balance sheet. This ratio, which compares total debt to shareholder equity, suggests a conservative approach to borrowing. The company also reported a current ratio of roughly 1.6x, indicating it has enough short-term assets to cover its immediate liabilities. Free cash flow, or the cash left after paying for operating costs and capital expenditures, reached approximately $7.4 billion in FY 2025.

The case for Intuitive Surgical

Intuitive Surgical is the pioneer of robotic-assisted surgery, primarily through its da Vinci and Ion systems. The company operates a "razor and blade" business model, where the initial sale of a robotic system leads to years of recurring revenue from instruments, accessories, and maintenance services. Its primary customers are hospitals and ambulatory surgery centers, and it has recently expanded its direct sales reach into several European markets to improve its medical device stocks presence.

In FY 2025, revenue reached roughly $10.1 billion, which was a significant increase of approximately 20.5% over the prior year. Net income for the same period was close to $2.9 billion, yielding a strong net margin of nearly 28.4%. This robust profitability is driven by the high volume of surgical procedures performed using its installed base of robots worldwide.

As of its December 2025 balance sheet, the company has a debt-to-equity ratio of 0.0x, indicating that shareholder equity far exceeds its total debt. Its current ratio stands at approximately 4.9x, showing a very high level of liquidity to meet short-term obligations. Free cash flow for FY 2025 was nearly $2.5 billion. Note that stock-based compensation represented roughly 26% of operating cash flow, which inflates reported cash generation since SBC is a non-cash expense added back in the cash flow statement.

Risk profile comparison

Abbott Laboratories faces risks related to its complex manufacturing and supply chain, particularly its reliance on single-source suppliers for certain products. The company is also dealing with significant ongoing litigation involving product liability claims for infant formula and potential False Claims Act allegations. Intense competition from rivals like Medtronic (NYSE:MDT) and Johnson & Johnson (NYSE:JNJ) means Abbott must constantly innovate to protect its market share in the medical device and diagnostics sectors.

Intuitive Surgical faces competition from alternative surgical approaches and new robotic entrants like Medtronic and SS Innovations International (NASDAQ:SSII). Macroeconomic pressures could lead hospitals to tighten their capital spending budgets, potentially delaying the purchase of expensive new robotic systems. Additionally, the company is vulnerable to supply chain issues involving rare earth elements and must navigate increasingly strict global regulations regarding AI-enabled medical devices and patient data privacy.

Valuation comparison

Abbott Laboratories appears to be the more conservatively priced option, while Intuitive Surgical carries a higher premium due to its faster revenue growth.

Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

The Forward P/E ratio compares the current stock price to future earnings estimates, while the P/S ratio measures the market value against sales over the past twelve months.

Which stock would I buy in 2026?

I'd go with Intuitive Surgical. Its installed base of nearly 12,000 da Vinci surgical systems is a major, durable competitive advantage in healthcare. Once a hospital has trained its surgeons on the platform and built its workflows around it, switching is rarely worth the disruption. Recurring revenue accounts for roughly 85% of total revenue, procedures grew at a strong double-digit rate in the most recent quarter, and the company beat earnings estimates by a wide margin while raising its gross margin outlook.

Abbott Laboratories deserves credit for running a well-diversified healthcare business across medical devices, diagnostics, and nutrition, and its acquisition of Exact Sciences adds a more exciting diagnostics story. For investors who want broad healthcare exposure alongside a growing dividend, it is a solid choice.

But Intuitive is growing faster, with a more focused business and a platform that keeps deepening its relationships with every hospital that adopts it. For a patient investor, that compounding advantage is worth owning.

Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories, Intuitive Surgical, and Medtronic. The Motley Fool recommends the following options: long January 2028 $520 calls on Intuitive Surgical and short January 2028 $530 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.

Whether it's biotech stocks or regular pharmaceutical stocks, when investors buy a particular name in healthcare, they are making a wager on a single company's pipeline. However, there is one unique name within this space that enables investors to gain more diversified exposure to current and potential future blockbuster drugs: Royalty Pharma (NASDAQ: RPRX).

Operating like both a biopharma company and a venture capital firm, Royalty provides capital to both for-profit drugmakers and nonprofit researchers, such as universities, in exchange for percentage ownership in their developed or underdeveloped drug candidates.

With the stock trading at a relatively low valuation, despite owning royalty interests in 16 blockbuster drugs, not to mention a slew of promising drug candidates, much suggests this is a gem among healthcare stocks that's still getting discovered by the market.

Image source: Getty Images.

Three reasons why Royalty Pharma is a drug stock standout

I know what you are thinking: Why buy Royalty Pharma when investors can simply buy multiple drug stocks?

For one, while you could go ahead and attempt to build a diversified portfolio of drug candidate stocks, why not let Royalty Pharma's management team do the heavy lifting for you? Operating with a lean overhead that accounts for only 5.5%-6.5% of portfolio receipts, Royalty Pharma offers a team of experienced pharmaceutical executives and capital allocators dedicated to investing in royalty deals that generate solid returns on invested capital.

This brings us to Royalty Pharma's second key strength: the advantageous way that it structures its royalty deals. A prime example of this is one of the company's latest unsuccessful investments. In September, Novartis and its biotech partner Ionis Pharmaceuticals unveiled disappointing clinical trial data for its experimental heart drug pelacarsen.

Royalty Pharma, through a prior funding agreement with Ionis, held a royalty interest in pelacarsen, but just because this candidate failed doesn't mean Royalty is out of its investment. As disclosed in a Sept. 4 press release, the funding deal coupled exposure to pelacarsen with ownership in "stable and predictable" royalties from another drug, Spinraza. In short, while pelacarsen's failure limits upside potential, the company still expects to generate a positive return from this investment.

Third, thanks to the favorable way Royalty Pharma structures deals and manages risk, it has built a long track record of double-digit annualized returns on invested capital. As noted in its latest quarterly earnings release, Royalty Pharma's average return on invested capital and equity was 14.9% and 21.5%, respectively, between 2019 and 2025. For Q2 2026, these figures stood at 14.2% and 20.1%, respectively. During the quarter, management also reported 14% growth in royalty receipts.

An overlooked gem still entering prime time

Since the start of the year, Royalty Pharma shares have surged over 50%. Price discovery is clearly taking shape as investors catch on to this company's unique strengths and impressive track record.

However, don't assume price discovery has completed just yet. Based on analyst estimates calling for adjusted earnings per share (EPS) of $5.34 during 2026 and $5.73 during 2027, Royalty Pharma seems like it's at the lower end of the valuation range among biopharma stocks. Yes, critics can counter this by pointing out that these strong adjusted earnings are relatively recent. For 2023, 2024, and 2025, Royalty Pharma reported EPS of $2.54, $1.93, and $1.80 per share, respectively.

However, with the company now scaled up and generating steady royalties and portfolio receipts from its blockbuster drugs, shares could be in for some serious multiple expansion if it meets or beats the aforementioned analyst forecasts. Established, profitable biotechs such as Amgen and Regeneron Pharmaceuticals trade at price-to-earnings (P/E) multiples in the high teens and low 20s.

Sure, contrary to this bull case, there are numerous long-term risks with Royalty Pharma. The company regularly issues new shares to finance expansion. In time, this dilution could weigh on long-term returns. Growing competition in the pharma royalty investment space could affect future returns.

Nevertheless, until Royalty Pharma's fiscal results and guidance more strongly reflect these risks, err on the side of optimism and consider this a long-term buy for investors seeking exposure to pharmaceutical stocks.

Thomas Niel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen, Ionis Pharmaceuticals, and Regeneron Pharmaceuticals. The Motley Fool has a disclosure policy.